Details of Disease

General Information of Disease (ID: DISDGALM)

• Disease Name: Sweetener
• Synonyms: Afnd; Gomm button disease; Gomm-button disease; neutrophilic dermatosis, acute febrile; sweet syndrome; acute febrile neutrophilic dermatosis
• Disease Class: N.A.: Sweetener
• Definition: Sweet's syndrome (the eponym for acute febrile neutrophilic dermatosis) is characterized by a constellation of clinical symptoms, physical features, and pathologic findings which include fever, neutrophilia, tender erythematous skin lesions (papules, nodules, and plaques), and a diffuse infiltrate consisting predominantly of mature neutrophils that are typically located in the upper dermis.
• Disease Hierarchy:
  DIS6SVEE: Syndromic disease
  DIS9YPUQ: Dermatological disease
  DIS77ACK: Rheumatic disorder
  DISDGALM: Sweetener
• ICD Code: ICD-11: ICD-11: N.A.
• Disease Identifiers:
  MONDO ID: MONDO_0011959
  MESH ID: D016463
  UMLS CUI: C0085077
  OMIM ID: 608068
  MedGen ID: 43097
  Orphanet ID: 3243
  SNOMED CT ID: 84625002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Stevioside	DMSYABW	Approved	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CTSS	TTUMQVO	Strong	Altered Expression	[2]
HBA2	TTQO71U	Strong	Genetic Variation	[3]

This Disease Is Related to 10 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AQP8	OT99JKME	Strong	Biomarker	[4]
DYM	OTQ670WI	Strong	Biomarker	[5]
GDF6	OTERXWJU	Strong	Biomarker	[6]
HBG1	OTVL4NSU	Strong	Biomarker	[7]
HBG2	OT4J48JJ	Strong	Genetic Variation	[8]
NELFCD	OTOLTZPU	Strong	Altered Expression	[9]
PMCH	OT3D9SA4	Strong	Altered Expression	[10]
PUF60	OTG90DYF	Strong	Biomarker	[11]
TSPYL2	OTGGW2EF	Strong	Genetic Variation	[12]
RAD23B	OT0PGOG3	Definitive	Genetic Variation	[13]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Longitudinal analysis of tear cathepsin S activity levels in male non-obese diabetic mice suggests its potential as an early stage biomarker of Sjgren's Syndrome.Biomarkers. 2019 Feb;24(1):91-102. doi: 10.1080/1354750X.2018.1514656. Epub 2018 Sep 12.
• [3] Influence of alpha thalassaemia on the retinopathy of homozygous sickle cell disease.Br J Ophthalmol. 1993 Feb;77(2):89-90. doi: 10.1136/bjo.77.2.89.
• [4] Antibodies to aquaporins are frequent in patients with primary Sjgren's syndrome.Rheumatology (Oxford). 2017 Dec 1;56(12):2114-2122. doi: 10.1093/rheumatology/kex328.
• [5] Influence of TGF-1 expression in endothelial cells on smooth muscle cell phenotypes and MMP production under shear stress in a co-culture model.Cytotechnology. 2019 Apr;71(2):489-496. doi: 10.1007/s10616-018-0268-7. Epub 2019 Feb 1.
• [6] KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model.Clin Exp Metastasis. 2010 Dec;27(8):591-600. doi: 10.1007/s10585-010-9349-5. Epub 2010 Sep 16.
• [7] Sequence variations in the 5' flanking and IVS-II regions of the G gamma- and A gamma-globin genes of beta S chromosomes with five different haplotypes.Blood. 1991 Jun 1;77(11):2488-96.
• [8] Certain mutations observed in the 5' sequences of the G gamma- and A gamma-globin genes of beta S chromosomes are specific for chromosomes with major haplotypes.Acta Haematol. 1991;85(2):79-87. doi: 10.1159/000204862.
• [9] T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum.Clin Exp Immunol. 2017 Sep;189(3):383-391. doi: 10.1111/cei.12989. Epub 2017 Jun 23.
• [10] A comparison of sickle cell syndromes in northern Greece.Br J Haematol. 1991 Mar;77(3):386-91. doi: 10.1111/j.1365-2141.1991.tb08589.x.
• [11] The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy.Clin Rheumatol. 2018 Jun;37(6):1573-1580. doi: 10.1007/s10067-018-4031-4. Epub 2018 Mar 15.
• [12] Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients.Oncoimmunology. 2018 May 31;7(8):e1467856. doi: 10.1080/2162402X.2018.1467856. eCollection 2018.
• [13] Contribution of STAT3 and RAD23B in Primary Szary Cells to Histone Deacetylase Inhibitor FK228 Resistance.J Invest Dermatol. 2019 Sep;139(9):1975-1984.e2. doi: 10.1016/j.jid.2019.03.1130. Epub 2019 Mar 22.